Galapagos NV (GXEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos NV (GXEA) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-82.75 Million ≈ $-96.74 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Galapagos NV (GXEA) market capitalisation for the company's overall valuation and market capitalisation.
Galapagos NV - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Galapagos NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galapagos NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ranked by their cash flow conversion efficiency. Explore Galapagos NV earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lucid Group Inc
NASDAQ:LCID
|
-0.582x |
|
Aygaz AS
IS:AYGAZ
|
0.003x |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
-0.079x |
|
Skywater Technology Inc
NASDAQ:SKYT
|
-0.028x |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
0.030x |
|
Bros Eastern Co Ltd
SHG:601339
|
0.071x |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
0.017x |
|
Absci Corp
NASDAQ:ABSI
|
-0.153x |
Annual Cash Flow Conversion Efficiency for Galapagos NV (2016–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV from 2016 to 2025. View current stock price of Galapagos NV for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-257.46 Million ≈ $-300.99 Million |
-0.080x | +27.98% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +40.49% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-518.97 Million ≈ $-606.73 Million |
-0.186x | +6.32% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | -- |
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more